Richard Goldstein, DVM, earned his veterinary degree from the Hebrew University of Jerusalem’s Koret School of Veterinary Medicine in Rehovot, Israel, and then completed an internship in small animal medicine and surgery. He is the chief medical officer and staff director at the Animal Medical Center (AMC) in New York City. Before joining the AMC, Goldstein was a faculty member in the Department of Clinical Sciences at Cornell University College of Veterinary Medicine, where he most recently served as an associate professor of small animal medicine and chief of the medicine service. He is board certified in small animal internal medicine by both the American College of Veterinary Internal Medicine and the European College of Veterinary Internal Medicine–Companion Animals.
Richard Goldstein, DVM, DACVIM (SAIM), DECVIM-CA, global chief medical officer at Zoetis, discusses what the pharmacovigilance data show, why the company brought in independent experts to review it, and how veterinarians should talk with pet owners about the benefits and risks associated with Librela.
In the US, 66% of households own a pet. That’s almost 87 million homes. Even more striking, 97% of US pet owners consider their animals to be part of the family. This may not come as a surprise for those of us in the veterinary field, but it does underscore the growing demand for veterinary services — placing considerable pressure on our dedicated veterinary healthcare teams.
To help confirm a diagnosis of canine leptospirosis, veterinarians today must rely on serologic testing with the microscopic agglutination test. Interpreting the test can be problematic, though, especially early on in the disease or in a recently vaccinated dog.
Obvious clinical signs may be apparent in only about 5% to 10% of dogs infected with B. burgdorferi. So the harder question is, how should we manage the vast majority of infected dogs that show no clinical signs?
